VXRT - CONSENSUS CO - Vaxart, Inc.

Vaxart, Inc. (VXRT) develops unique tablet-based medications, eliminating the need for injections and costly cold-chain systems. The business targets the public sector, offering streamlined logistics for large-scale immunization against COVID and influenza. The current metric stands at . The price action on the chart below complements the data on the company, whose operations are strictly regulated by FDA standards for biomaterial disposal.

Vaxart, Inc. (VXRT) dependence on government grants and the risks associated with the failure of tablet vaccine trials render the asset's value extremely volatile. The analysts' median price forecast aggregates expert fair value estimates, filtering market noise through a weighted average of target prices, which allows investors to compare the company's fundamental potential with current quotes and determine the expected return over a one-year horizon.